Commenting on the new developments, CluePoints CEO, Andy Cooper, said: “While traditional Risk-Based Quality Management (RBQM) complements people and processes with data and technology, the future will look to AI and deep learning to further interrogate data and processes and enable improved risk assessment. CluePoints sees a huge opportunity for further growth as RBQM pushes boundaries even further into these areas and therefore has appointed the expertise of Amit Patel to capitalise on this opportunity as our CFO. We are, therefore, proactively scaling up and investing in the best talent, a world-class product portfolio and strategic leadership to fulfil our ambitions and meet the extraordinary demand we are experiencing. It is an exciting time to be part of a world-class organisation pushing the boundaries to support excellent clinical trial execution.”
About CluePointsCluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. Our products utilise comprehensive statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints
® is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation you now have everything you need to adhere with global regulatory guidance. The result is increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM. For further information on CluePoints’ solutions and developments, please visit
www.cluepoints.com.